Clinical Trials Logo
NCT number NCT03190304
Study type Interventional
Source University of Sao Paulo General Hospital
Contact Marcelo R Santos, PhD
Phone +55 11 2661-5043
Email marcelo.rs@usp.br
Status Recruiting
Phase Phase 4
Start date June 14, 2017
Completion date December 14, 2018

Clinical Trial Summary

Studies with new drugs in the treatment of heart failure (HF), such as the combination of valsartan/sacubitril, also known as LCZ696, have demonstrated important clinical impact on the morbidity and mortality outcomes in HF population. However, the effect of LCZ696 on the pathophysiological mechanisms of HF such as exercise tolerance (peak VO2) and peripheral muscle blood flow is not known. Since LCZ696 is a new drug with promising effects on the treatment of HF, the objective of the present study will be to evaluate the effect of LCZ696 in patients with HF on: 1) peak VO2, 2) 6-minute walk test, 3) peripheral muscle blood flow, 4) muscle strength, and 5) body composition.


Clinical Trial Description

Heart failure (HF) with reduced ventricular ejection fraction is a disease that affects around 5.7 million people in the United States, with a mortality rate of approximately 50% within 5 years. HF is characterized by an exacerbation of the renin-angiotensin-aldosterone system (RAAS), which leads to an increase in sympathetic nerve outflow, peripheral vasoconstriction, and reduced functional capacity. Moreover, many clinical trials have been developed for the treatment of HF patients focused on inhibition of RAAS, such as enalapril. Nevertheless, hospitalization and mortality rates in this population are excessive. However, studies with new drugs, such as the combination of valsartan/sacubitril, also known as LCZ696, have demonstrated important clinical impact on the morbidity and mortality outcomes in HF population. However, the effect of LCZ696 on the pathophysiological mechanisms of HF such as exercise tolerance (peak VO2) and peripheral muscle blood flow is not known. Since LCZ696 is a new drug with promising effects on the treatment of HF, the objective of the present study will be to evaluate the effect of LCZ696 in patients with HF on: 1) peak VO2, 2) 6-minute walk test, 3) peripheral muscle blood flow, 4) muscle strength, and 5) body composition.


Study Design


Related Conditions & MeSH terms


See also
Status Clinical Trial Phase
 Not yet recruiting NCT02922036 - Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-Responders and Previously Untreatable Patients Phase 3
 Not yet recruiting NCT03170466 - Primary Palliative Care in Heart Failure: A Pilot Trial N/A
 Not yet recruiting NCT02784912 - Biomarkers in Risk Stratification of Sustainted Ventricular Tachycardia or Electrical Storm After Ablation N/A
 Not yet recruiting NCT03003780 - Mindful Steps: Promoting Physical Activity N/A
 Recruiting NCT03013270 - Aerobic, Resistance, Inspiratory Training Outcomes in Heart Failure N/A
 Recruiting NCT03071952 - Assessment of AAIR Pacing Treatment for Heart Failure Patients With Chronotropic Incompetence N/A
 Recruiting NCT02713126 - Inorganic Nitrite to Amplify the Benefits and Tolerability of Exercise Training in HFpEF (INABLE-Training) Phase 2
 Recruiting NCT02864420 - Hospitalization at Home: The Acute Care Home Hospital Program for Adults N/A
 Recruiting NCT02921607 - Development of Scalable New Model(s) Focused on Care Co-ordination and Care Provision for Medically Complex, Co-morbid Chronic Disease Patient Segments Focusing on Heart Failure N/A
 Recruiting NCT02911493 - Reducing Sedentary Time in Patients With Heart Failure N/A
 Recruiting NCT02914665 - A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure Phase 2
 Recruiting NCT02823795 - The Supporting Patient Activation in Transition to Home Intervention N/A
 Active, not recruiting NCT02922478 - Role of Comorbidities in Chronic Heart Failure Study N/A
 Withdrawn NCT02624960 - Safety and Performance of the AccuCinch® System N/A
 Not yet recruiting NCT02899364 - Sodium Thiosulfate to Preserve Cardiac Function in STEMI Phase 2
 Not yet recruiting NCT02821065 - Telehealth for Emergency-Community Continuity of Care Connectivity Via Home-Telemonitoring N/A
 Not yet recruiting NCT02903940 - The Application of Negative Atrioventricular Hysteresis in Cardiac Resynchronization Therapy N/A
 Not yet recruiting NCT02877914 - China PEACE 5r-HF Study N/A
 Recruiting NCT02598505 - Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation Phase 3
 Recruiting NCT03092284 - Allogeneic Stem Cell Therapy in Heart Failure Phase 2